$MDXG (MiMedx Group, Inc.)

$MDXG {{ '2016-01-11T16:16:26+0000' | timeago}} • Announcement

$MDXG said it agreed to buy Stability Biologics, provider of human tissue products. $MDXG sees deal to be accretive to Adjusted EPS in 2016, and sees 2016 Stability Biologics revenues generated from processed tissue and bone product sales and distribution to be at least $15MM. The deal is expected to close by mid-Jan.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

$JNJ {{ '2017-07-17T15:58:16+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 3Q17 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017 to shareholders of record as on August 29, 2017. The ex-dividend date is August 25, 2017.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MMM {{ '2017-06-30T15:31:24+0000' | timeago}} • Announcement

$MMM completed the sale of its tolling and automated license/number plate recognition business to Neology, which is a subsidiary of SMARTRAC, a portfolio company managed by One Equity Partners. The impact of the transaction will be neutral to both 2Q17 and full-year 2017 GAAP EPS.

$JNJ {{ '2017-06-27T15:40:39+0000' | timeago}} • Announcement

DePuy Synthes Products, part of the $JNJ, acquired Innovative Surgical Solutions LLC, doing business as Sentio LLC, a privately-held company based in Wixom, Michigan that markets innovative nerve localization technology for spine surgery. Financial terms of the transaction have not been disclosed.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$HAE {{ '2017-06-23T10:51:04+0000' | timeago}} • Announcement

$HAE announced the formation of a Scientific Advisory Council as part of its broader innovation agenda, advancing its commitment to science and clinical excellence. The SAC will also, as appropriate, provide opinion on strategic issues impacting product and clinical matters.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$MDT {{ '2017-06-19T11:01:15+0000' | timeago}} • Announcement

$MDT said its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA Europace-Cardiostim 2017.

Recent Transcripts

JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
CAH (Cardinal Health, Inc.)
Monday, May 1 2017 - 12:30pm
MDXG (MiMedx Group, Inc.)
Friday, April 28 2017 - 2:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, April 18 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Monday, February 27 2017 - 10:30pm

AlphaGraphics you may like